● satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with current good manufacturing practices, or cGMP, and to assure that the facilities, methods and controls are adequate to preserve the drug's identity, strength, quality and purity, as well as satisfactory completion of an FDA inspection of selected clinical sites to determine cGCP compliance; and Preclinical Studies. Preclinical studies include laboratory evalua ...

RUN-IN Double Blind Treatment Period Long-term Safety Extension Treatment Period (Open Label) 7 Days 8 Weeks Up to 52 Weeks Part B and Second Study Oral DFK XX mg BID Oral PBO BID Initiation Part A NP Phase 2/3 (1Q 2023) | --- | |-------------| | | | | | KIND 1b & 2 | | AD Phase 3 | 15 $180M cash position September 30, 2022 • Sufficient resources to continue development of the oral difelikefalin platforms CCARA THERAPEUTICS Prim ary Endpoint KARE STUDY: Phase 2 Data in Atopic Dermatitis (AD) Popula t ion: M ...

Cara Therapeutics, Inc. (NASDAQ:CARA) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Matthew Murphy - Manager, Investor Relations Christopher Posner - President, CEO & Director Ryan Maynard - CFO Joana Goncalves - Chief Medical Officer Conference Call Participants Sumant Kulkarni - Canaccord Genuity Joseph Stringer - Needham & Company Daniel Wolle - JPMorgan Chase & Co. Chi Meng Fong - Bank of America Merrill Lynch Stacy Lee - Stifel David Amsellem - Piper Sandler & Co. Op ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-36279 CARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 75-3175693 (State or other jurisdiction of inc ...

Cara Therapeutics, Inc. (NASDAQ:CARA) Q2 2022 Results Conference Call August 8, 2022 4:30 PM ET Company Participants Iris Francesconi - Head of Investor Relations Christopher Posner - President and Chief Executive Officer Richard Makara - Interim Chief Financial Officer Joana Goncalves - Chief Medical Officer Conference Call Participants Daniel Wolle - JPMorgan Christopher Howerton - Jefferies Joseph Stringer - Needham & Company David Amsellem - Piper Sandler Oren Livnat - H.C. Wainwright Jason Gerberry - B ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-36279 CARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 75-3175693 (State or other jurisdiction of incorpor ...

Cara Therapeutics, Inc. (NASDAQ:CARA) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Iris Francesconi - Interim Head, Investor Relations Chris Posner - President & Chief Executive Officer Tom Reilly - Chief Financial Officer Joana Goncalves - Chief Medical Officer. Conference Call Participants Joseph Stringer - Needham & Company Chi Tran - Bank of America Daniel Wolle - JPMorgan David Amsellem - Piper Sandler Sumant Kulkarni - Canaccord Oren Livnat - H.C. Wainwright Operator G ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-36279 CARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 75-3175693 (State or other jurisdiction of incorpo ...

Welcome to Cara Therapeutics 2022 R&D Day MARCH 11, 2022 Forward Looking Statements Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forwardlooking statements include statements concerning the expected timing of the initiation, enrollment and data readouts from the Company's planned and ongoing clinical trials, the potential results of ongoin ...

Cara Therapeutics, Inc. (NASDAQ:CARA) Q4 2021 Earnings Conference Call March 1, 2022 4:30 PM ET Company Participants Iris Francesconi - Interim Head, Investor Relations Christopher Posner - President, CEO & Director Thomas Reilly - CFO Joana Goncalves - Chief Medical Officer Conference Call Participants Joseph Stringer - Needham & Company Nicholas Rubino - Stifel, Nicolaus & Company Sumant Kulkarni - Canaccord Genuity Chi Zhang - Bank of America Merrill Lynch Daniel Wolle - JPMorgan Chase & Co. David Amsell ...